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Successful reconstitution of cytomegalovirus (CMV)-specific CD8+ T cells by hemato-
poietic cell transplantation (HCT) gives a favorable prognosis for the control of CMV 
reactivation and prevention of CMV disease after hematoablative therapy of hematopoi-
etic malignancies. In the transient immunocompromised state after HCT, pre-emptive 
cytoimmunotherapy with viral epitope-specific effector or memory CD8+ T cells is a 
promising option to speed up antiviral control. Despite high-coding capacity of CMVs 
and a broad CD8+ T-cell response on the population level, which reflects polymorphism 
in major histocompatibility complex class-I (MHC-I) glycoproteins, the response in 
terms of quantity of CD8+ T cells in any individual is directed against a limited set of 
CMV-encoded epitopes selected for presentation by the private repertoire of MHC-I 
molecules. Such epitopes are known as “immunodominant” epitopes (IDEs). Besides 
host immunogenetics, genetic variance in CMV strains harbored as latent viruses by an 
individual HCT recipient can also determine the set of IDEs, which complicates a “per-
sonalized immunotherapy.” It is, therefore, an important question if IDE-specific CD8+ 
T-cell reconstitution after HCT is critical or dispensable for antiviral control. As viruses 
with targeted mutations of IDEs cannot be experimentally tested in HCT patients, we 
employed the well-established mouse model of HCT. Notably, control of murine CMV 
(mCMV) after HCT was comparably efficient for IDE-deletion mutant mCMV-Δ4IDE 
and the corresponding IDE-expressing revertant virus mCMV-Δ4IDE-rev. Thus, anti-
genicity-loss mutations in IDEs do not result in loss-of-function of a polyclonal CD8+ 
T-cell population. Although IDE deletion was not associated with global changes in the 
response to non-IDE epitopes, the collective of non-IDE-specific CD8+ T-cells infiltrates 
infected tissue and confines infection within nodular inflammatory foci. We conclude 
from the model, and predict also for human CMV, that there is no need to exclusively aim 
for IDE-specific immunoreconstitution.
Keywords: adoptive cell transfer, cD8 T cells, cytomegalovirus, epitope prediction, hematopoietic cell 
transplantation, immunodominance, immunotherapy, reconstitution
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inTrODUcTiOn
Reactivation of human cytomegalovirus (hCMV), the prototype 
member of the β-subfamily of herpesviruses, continues to be a 
medical challenge in recipients of solid organ transplantation 
(SOT) as well as in the therapy of hematopoietic malignancies by 
hematoablative treatment followed by hematopoietic cell trans-
plantation (HCT) for reconstitution. In both cases, latent CMV 
is released from immune surveillance by a therapy-inherent 
immunosuppressive regimen, host-versus-graft reaction (graft 
rejection) prophylaxis in SOT, and hematoablative treatment as 
well as graft-versus-host disease prophylaxis in HCT. Notably, 
risk of graft failure after SOT is primarily associated with donor 
seropositivity for anti-hCMV antibodies (D+), which is indica-
tive of latent infection of the transplant donor, whereas in HCT 
risk of multiple-organ CMV disease is associated mainly with 
recipient seropositivity (R+) indicative of latent infection of the 
recipient [for reviews see Ref. (1–6)]. Although myeloid lineage 
hematopoietic progenitor cells are a recognized reservoir for 
latent hCMV and, thus, a potential source of reactivated virus 
[(7–11); for reviews see Ref. (12, 13)], the risk association in both 
SOT and HCT may point to latently infected non-hematopoietic 
stromal or parenchymal tissue cells as the primary source(s) of 
reactivated virus causing CMV organ disease. The model of 
murine CMV (mCMV) infection reflected the clinical correlate 
in that reactivation-competent latent virus was transmitted 
by experimental SOT (14–16) and failed to be transmitted by 
experimental HCT (17) but reactivated independently from 
multiple organs (18–21). Specifically, liver sinusoidal endothe-
lial cells (LSECs) proved to be a cellular site of mCMV latency 
and reactivation (22), and in explants of latently infected lung 
tissue, virus reactivation failed to colocalize with CD11b+ and 
CX3CR1+ cells of the hematopoietic myeloid differentiation 
lineage (23).
In clinical HCT with latently infected patients as recipients 
(R+), most cases of CMV disease are diagnosed 3–12  weeks 
after HCT [reviewed in Ref. (5)]. Thus, considering that minute 
amounts of reactivated virus need time to substantially multiply 
and spread before CMV disease can be diagnosed, reactivation 
apparently occurs rapidly after hematoablative treatment. Since 
reactivation is a stochastic and, thus, unpredictable event [(24, 
25), reviewed in Ref. (26–28)], murine models mimic a 100% 
“reactivation rate” by experimental primary infection shortly 
after experimental HCT for an easier statistical evaluation.
Early studies on immune reconstitution and CMV disease 
after clinical HCT have identified reconstitution of cytotoxic 
responses as a positive predictor for prevention of CMV disease 
(29). These findings were corroborated and further specified 
for recipients of HLA-matched clinical HCT by demonstrating 
that CMV pneumonia did not occur in patients in whom CD8+ 
HLA class-I restricted, hCMV-specific cytolytic T lymphocytes 
(CTL) developed in the course of hematopoietic reconstitution 
(30). While these clinical studies gave good correlative evi-
dence for prevention of CMV disease by CMV-specific CD8+ 
T cells, pre-emptive cytoimmunotherapy of CMV disease by 
adoptive transfer of purified polyclonal ex vivo populations 
or of virus epitope-specific clonal and non-clonal CTL lines 
(CTLL) or sorted CD8+ T cells provided “proof of concept” 
for antiviral protection by CD8+ T cells [reviewed in Ref. 
(31–34)]. This was pioneered by the mouse model (35, 36) and 
later confirmed in clinical trials (37–41). Supplementation of 
HCT with CMV-specific CD8+ T cells revealed that combined 
endogenous and adoptive reconstitution of antiviral CD8+ 
T cells prevents lethal CMV disease, limits latent virus burden, 
and reduces the risk of virus recurrence for late CMV disease 
in HCT recipients in the murine model (42). More recently, 
protective antiviral function of human CD8+ T cells specific 
for an hCMV UL83/pp65-derived peptide was also shown in 
an HLA-A2 transgenic mouse model upon challenge infec-
tion with a “humanized” mCMV recombinant expressing the 
hCMV epitope (43).
Inevitable death from multiple-organ CMV disease after HCT 
following depletion of pan-CD8+, but not of pan-CD4+ T cells, 
revealed that CD8+ effector cell function is essential for prevent-
ing CMV disease after HCT and excluded redundant control by 
innate or by other adaptive immune effector cell types [(44, 45), 
see also the accompanying Review article in this issue of Frontiers 
in Immunology]. The contribution of different viral epitopes to 
the protective reconstitution after HCT, however, is less well 
established.
Although hCMV and mCMV both have a high-coding 
capacity with the potential to encode numerous antigenic 
peptides presented by major histocompatibility complex class-I 
(MHC-I) molecules to the T-cell receptors (TCRs) of CD8+ 
T cells, the response in any individual person (46) as well as in 
mouse inbred strains (31–33, 47) is limited to only few epitopes 
selected by the individual HLA/MHC class-I genotype. The 
response is broad on the population level, accounting for HLA/
MHC polymorphism, but is narrow in any individual. Moreover, 
among the set of epitopes, only few give rise also to an easily 
detectable, numerically prominent in vivo response and are, thus, 
operationally classified as being “immunodominant” in terms 
of quantity. UL83/pp65 is the prototypic example of an hCMV 
protein that primes and expands a high proportion of CD8+ 
T cells [(48–51), reviewed in Ref. (52)], and in the mouse model 
an H-2Ld-presented m123/IE1-derived peptide is the prototype 
of an “IDE” [(53, 54), reviewed in Ref. (31)]. Although it was 
tempting to select such epitopes for adoptive immunotherapy or 
vaccine design, “immunodominance” in quantity is not neces-
sarily identical with “immunodominance” in protective function. 
Specifically, in the mouse model, adoptive transfer of epitope-
specific CTLL revealed an equally efficient antiviral protection 
with “subdominant” epitopes [reviewed in Ref. (32–34)], a find-
ing corroborated by DNA vaccination based on “subdominant” 
epitopes (55). In accordance with this, deletion of “IDEs” did 
not reduce the protective efficacy of mCMV-primed polyclonal 
CD8+ T cells upon adoptive transfer, regardless of whether these 
epitopes were missing in the cell transfer donor, the recipient, or 
both (56, 57).
In the cell transfer models, effector and memory cells, primed 
from naïve CD8+ T cells following CMV infection of an immu-
nocompetent host, were used for testing their antiviral function. 
This is not necessarily predictive for the protective contribution 
of “immunodominant” and “subdominant” viral epitopes after 
TaBle 1 | list of currently identified cD8+ T cell epitopes in the H-2d 
haplotype.
OrF antigenic  
peptide
Presenting 
Mhc-i
classification reference
m04 243YGPSLYRRF251 Dd Subdominant (74)
m18 346SGPSRGRII354 Dd Subdominant (75)
M45 507VGPALGRGL515 Dd Subdominant (76)
M54 83RGPYSDEL90 Dd Subdominant (70)
M83 761YPSKEPFNF769 Ld Subdominant (77)
M84 297AYAGLFTPL305 Kd Subdominant (78)
M105 207TYWPVVSDI215 Kd Dominant (56)
m123/IE1 168YPHFMPTNL176 Ld Dominant (53)
m145 451CYYASRTKL459 Kd Dominant (56)
m164 150AGPPRYSRI158 Dd Dominant (79, 89)
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HCT when CD8+ T cells are derived from hematopoietic lineage 
reconstitution and thymic selection in the presence of CMV. Here, 
we have analyzed the mCMV epitope-specific reconstitution of 
antiviral CD8+ T cells over time after syngeneic experimental 
HCT and addressed the question if deletion of all known “IDEs” 
has a loss-of-control phenotype comparable to pan-CD8+ T-cell 
depletion.
MaTerials anD MeThODs
Prediction algorithms for Processing 
scores and statistical analyses
Processing predictions (proteasomal cleavage/transporter associ-
ated with antigen processing/presentation (TAP)/MHC class-I 
combined predictor) were made using the IEDB analysis resource 
(http://tools.iedb.org/processing/). This tool predicts epitope 
candidates based on the processing of peptides in the cell. It 
combines predictors for proteasomal processing by the constitu-
tive proteasome or the immunoproteasome (58), TAP transport 
(59), and MHC-I binding (60) to produce an overall score for 
each peptide’s intrinsic potential of being a T-cell epitope. The 
MHC-I binding predictions were made on 3/08/2016 using the 
IEDB analysis resource Consensus tool (61), which combines 
predictions from ANN aka NetMHC 3.4 (62, 63), SMM (64), and 
Comblib (65).
The two-sided unpaired t-test with Welch’s correction of 
unequal variances was used to evaluate statistical significance 
of differences between two independent sets of log-transformed 
data. Differences were considered statistically significant for 
P-values of <0.05 (*) or highly significant for P-values of <0.001 
(**). Viral doubling times (vDT =  log2/a) in host organs and 
the corresponding 95% confidence intervals were calculated by 
linear regression analysis from the slopes a of log-linear growth 
curves (66). Frequencies of cells responding in the enzyme-
linked immunospot (ELISpot) assay and the corresponding 
95% confidence intervals were calculated by intercept-free 
linear regression analysis from the linear portions of regres-
sion lines based on spot counts from triplicate assay cultures 
for each of the graded cell numbers seeded. Calculations were 
performed with GraphPad Prism 6.04 (GraphPad Software, San 
Diego, CA, USA).
hematopoietic cell Transplantation, 
adoptive cell Transfer, and infection
Technical details of HCT (67), the immunomagnetic enrich-
ment (positive selection) of CD8+ T cells for adoptive transfer 
or for ELISpot assays (66), intravenous adoptive cell transfer/
cytoimmunotherapy (66), and intraplantar (footpad) infection 
(66) procedures were described by us previously in method book 
chapters. In brief, recipients of HCT as well as of T-cell transfer 
were 8-week-old female BALB/c (H-2d haplotype) mice, immuno-
compromised by hematoablative total-body γ irradiation with a 
single dose of 6.5 Gy. Cells were infused intravenously, usually 4 h 
after the hematoablative conditioning. For syngeneic HCT with 
BALB/c mice as donors and recipients, 5 ×  106 donor-derived 
femoral and tibial bone marrow cells (BMC), depleted of CD8+ 
cells by immunomagnetic separation, were infused. For adoptive 
cell transfer, CD8+ (memory) T cells were immunomagnetically 
purified from spleen cells of BALB/c donor mice primed to 
mCMV antigens by intraplantar infection at >3 months before 
use. Graded cell numbers were infused intravenously into 
corresponding groups of usually five immunocompromised 
recipients each. Intraplantar infection of the recipients of HCT 
or adoptive cell transfer was performed shortly thereafter with 105 
plaque-forming units (PFU) of the viruses mCMV-Smith [ATCC 
VR-194; derived from batch 9/75; (68)], mCMV-BACW [cloned 
bacterial artificial chromosome-derived virus MW97.01; (69)], 
BACW-derived mutant virus mCMV-Δ4IDE (57) or revertant 
virus mCMV-Δ4IDE-rev (70).
Mice were bred and kept under specified pathogen-free condi-
tions in the Central Laboratory Animal Facility (CLAF) at the 
University Medical Center of the Johannes Gutenberg-University 
Mainz.
assays for Ex Vivo Detection and 
Quantitation of Viral epitope-specific 
cD8+ T cells
ELISpot assays (each spot representing one responding 
cell), based on interferon (IFN)-γ secretion by primed viral 
epitope-specific CD8+ T cells upon restimulation with synthetic 
antigenic peptides, were performed for graded responder cell 
numbers and a fixed number of peptide-loaded stimulator cells 
(P815 mastocytoma cells, H-2d) in triplicate assay cultures as 
described in greater detail previously [(71), and references 
therein]. Lung-resident CD8+ T cells, which include cells in 
interstitial infiltrates and non-circulating cells trapped in the 
lung vasculature attached to the endothelium, were isolated in 
a kinetics post-HCT and infection with mCMV-Smith. Lungs 
were perfused but bronchoalveolar lavage was not performed 
in order to discard cells circulating in the blood of the lung 
vasculature but to retrieve cells localizing to the alveolar 
 epithelium (67, 72, 73).
Synthetic peptides corresponding to reported epitopes 
presented by MHC-I molecules Kd, Dd, and Ld were from open 
reading frames (ORFs) m04 (74), m18 (75), M45 (76), M83 (77), 
M84 (78), M105 (56), m123/IE1 (53), m145 (56), and m164 (79) 
(Table 1).
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For detecting also mCMV antigen-specific CD8+ T cells for 
which the epitope is not yet identified, a viral genome-wide ORF 
library of transfectants [for the principle of the ORF library 
screening, see Ref. (34, 47)] was used for stimulating memory 
spleen cells (pool from at least five mice per group) derived from 
HCT recipients in the phase of latency after clearance of produc-
tive infection with viruses mCMV-Δ4IDE and mCMV-Δ4IDE-
rev. After electronic gating on CD8+ T cells, sensitized cells were 
quantitated by cytofluorometric detection of intracellular IFN-γ 
as described in detail previously (66). For control, the same spleen 
cell populations were tested with the cytofluorometric intracel-
lular IFN-γ assay after stimulation with synthetic peptides cor-
responding to the set of known epitopes. A list allocating ORF 
library numbers to actual ORFs can be found in Table S1 in 
Supplementary Material of Ref. (56).
assays for Quantitating Peptide 
Processing and for Detecting cell  
surface Presentation
Naturally processed antigenic peptides, protected by MHC-I 
binding against degradation, were isolated from extracts of 
infected mouse embryo fibroblasts (MEF). They were quantitated 
by a bioassay with epitope-specific CTLL, generated as described 
previously (66), and the corresponding synthetic peptides for the 
standard curve (76, 80), applying methods essentially based on 
reference (81).
Presentation of peptide–MHC-I (pMHC-I) complexes at the 
cell surface of infected MEF was detected with the correspond-
ing epitope-specific CTLL in the IFN-γ-based ELISpot assay 
(see above, except that infected MEF were used as stimulator 
cells). MEF infection was performed with 0.2 PFU per cell under 
conditions of “centrifugal enhancement of infectivity” (67), 
which results in an effective multiplicity of infection (MOI) of 4. 
For mapping presentation to the kinetic phase of the viral gene 
expression program, MEF were metabolically arrested in the 
“immediate-early” (IE) and “early” (E) phases, as described (67), 
or were allowed to proceed to the “late” (L) phase in absence of 
inhibitors.
assays for Quantitating In Vivo infection 
and Formation of nodular inflammatory 
Foci
Infectious virus in host organs was quantitated in terms of PFU 
by testing organ homogenates in a virus plaque assay on MEF 
under conditions of “centrifugal enhancement of infectivity” (see 
above), as described in greater detail previously (67).
To evaluate and quantitate infection in the microanatomical 
context of host tissues, specifically of liver tissue, imaging of 
infected cells in tissue sections was performed by immunohisto-
chemical (IHC) staining of intranuclear IE1 protein. For detecting 
nodular inflammatory foci (NIF), a two-color IHC was performed 
combining the staining of infected cells expressing intranuclear 
IE1 protein and the staining of T cells expressing CD3ϵ at the 
cell membrane. IHC methods are described in greater detail in 
method book articles (66, 67).
resUlTs
high Dynamics and Variance of epitope-
specific cD8+ T-cell reconstitution after 
hcT
CD8+ T-cell responses are usually characterized by a peak of 
the primary response during which naïve CD44lowCD62Lhigh T 
cells are primed to yield CD44highCD62LlowKLRG1high cytolytic 
effector cells (TE) as well as memory cells (TM), subdivided into 
CD44highCD62LlowKLRG1low effector-memory cells (TEM) and 
CD44highCD62LhighKLRG1low central memory cells (TCM). This 
acute response is followed by a phase of contraction to a primar-
ily lymphoid tissue-resident pool of TCM that can initiate a recall 
response with recruitment to extra-lymphoid sites of antigen 
presentation [reviewed in Ref. (82)]. In difference to this general 
scheme, the CD8+ T-cell response to CMVs is characterized by a 
contraction phase being followed by a more or less continuous 
increase in the pool size also of extra-lymphoid CD8+CD62Llow 
T cells specific for certain viral epitopes. This phenomenon 
was first described in the HCT model of mCMV infection for 
pulmonary CD8+CD62Llow cells, then referred to as TEM, specific 
for two H-2d-restricted epitopes in the BALB/c mouse strain (79, 
83). It was later extended to non-HCT models, other organ sites, 
and to the H-2b haplotype (84), and was coined with the term 
“memory inflation (MI)” (85). The “inflationary” cells assume 
the phenotype of short-lived effector cells [SLECs (82)], namely 
CD44highCD62LlowCD127lowKLRG1high (86). It is current view that 
MI is related to viral latency [reviewed in Ref. (27, 28)] and is 
driven in the intravascular compartment (73) by sporadic viral 
gene expression events in latently infected non-hematopoietic 
cells (87, 88), such as endothelial cells, including the LSECs in 
the liver sinusoids, a defined cellular site of mCMV latency and 
reactivation (22).
We have here retrospectively compiled data on epitope-
specific (for a list of currently defined mCMV epitopes in the 
H-2d haplotype, see Table  1) CD8+ T-cell reconstitution and 
recruitment into the pulmonary pool from three experimental 
HCTs performed independently over the years under nominally 
identical experimental conditions, including identical age of the 
HCT recipients as an important parameter of expectable thymic 
T-cell output.
In absolute terms, the yield of pulmonary infiltrate CD8+ 
T cells (Figure  1A) peaked during acute lung infection in 
weeks 4–5 at ca. 106 cells in all three HCTs, which is in good 
accordance with previous findings in this model [(54), see also 
the accompanying Review article in this issue of Frontiers in 
Immunology]. Also in agreement with previous findings is the 
subsequent decline in the absolute numbers, corresponding with 
cleared productive infection and establishment of latent infec-
tion, but also the long-term persistence of an elevated level of 
tissue-resident CD8+ T cells compared to a control HCT with 
no infection (45, 83). Notably, as shown previously, long-term 
tissue-resident CD8+ T cells are not exhausted but are functional 
in that they can control infection upon adoptive transfer into 
infected immunocompromised recipients (45). While HCT #1 
and HCT #3 were similar in the time course, HCT #2 showed a 
FigUre 1 | Dynamics of pulmonary cD8+ T-cell infiltration after hcT 
and infection. One-year follow-up of CD8+ T-cell reconstitution and 
pulmonary infiltration in mCMV-Smith-infected BALB/c HCT recipients for 
three independent HCTs (HCT #1, #2, and #3) performed under identical 
conditions. (a) Average total yield of immunomagnetically purified CD8+ T 
lymphocytes per lung isolated from a pool of lungs of at least four HCT 
recipients per time point. (B) Proportion of CD8+ T lymphocytes among 
pulmonary TCRα/β+ T cells, determined by cytofluorometric analysis of 
isolated lung infiltrate cells.
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striking discontinuity in that the peak was followed by a rapid 
1-log decline and slow recovery until values returned to the “viral 
latency-associated” level of the two other HCTs. We do not know 
what an event has caused such a rapid sinking in the lungs in 
HCT #2, possibly a non-diagnosed other infection detracting the 
cells from the lungs to other locations, but one must be aware 
of the fact that unpredictable events may happen also in HCT 
patients, who all have individual histories of malignant disease 
and treatment, and of unknown antigen encounters in the phase 
of reconstitution.
Whereas absolute numbers are prone to variance in isolation 
efficiency, proportions are less influenced by technical param-
eters. Similar as described previously for this model (54), CD8+ T 
cells dominated the pulmonary TCRα/β T-cell infiltrates during 
acute lung infection in all three HCTs (Figure 1B). In this respect, 
HCT #3, rather than HCT #2 (see above), was exceptional in that 
a particularly high proportion of CD8+ T cells at week 4 dropped 
markedly within a week.
All in all, independently performed but otherwise identical 
HCTs showed a similar course of CD8+ T-cell reconstitution and 
lung infiltration in the more cardinal parameters of peak tissue 
infiltration during acute lung infection, followed by decline and 
long-term tissue-residency during latent infection of the lungs, 
but with occasional short-term fluctuations.
In order to monitor for viral epitope-specific pulmonary 
CD8+ T-cell expansions and contractions, we determined the 
response hierarchy profiles defined by frequencies of CD8+ 
T  cells responding to the presentation of a panel of antigenic 
peptides (Figure  2). In essence, for an observation period of 
1 year, epitope-specific responses were highly variable between 
the three HCTs and far from continuity within any of the three 
HCTs. For the response to IDEs m123/IE1 and m164, both of 
which are expressed in the IE phase of the viral gene expression 
program (53, 89), the time of the peak acute response was variable 
and contraction was not pronounced. One may discuss contrac-
tion at 10 and 6 weeks in HCT #1 and HCT #3, respectively, but 
not in HCT #2. However, after the establishment of viral latency, 
which under conditions of HCT is beyond 4 months (87), the 
established “MI epitopes” m123/IE1 and m164 dominated in 
accordance with previous findings (79). Note that two additional 
IDEs, namely M105 and m145 (56), were not yet known when 
the three HCTs were performed. Likewise, non-IDE M54 has 
been identified only recently (70). Strikingly, certain epitopes 
classified in immunocompetent mice as “subdominant” or non-
IDEs, transiently popped up, for instance, m18 (weeks 4, 6, and 
20) and M83 (weeks 6 and 20) in HCT #1, m18 (weeks 4 and 
5) and M83 as well as M84 (week 6, and to a lower level after 
1  year) in HCT #2, and m18 (weeks 3 and 4, and declined in 
week 5) and M83 (week 3) in HCT #3. While m18, M83, and 
M84 were seen repeatedly and in all three HCTs, the time of their 
response involvement was highly variable. Most notably, in HCT 
#3, CD8+ T cells specific for the non-IDE m18 expanded to tran-
sient immunodominance between weeks 3 and 4, concomitant 
with the above discussed sharp increase in the overall propor-
tion of CD8+ T cells in the lung infiltrates (recall Figure  1B). 
Accordingly, concomitant with the subsequent decline in the 
overall proportion, m18-specific CD8+ T cells vanished and 
never reappeared.
Honestly, we do not really know why clones of a certain 
epitope specificity flash and become extinct. General availability 
of growth factors for clonal expansion, such as interleukin-2, is 
unlikely an explanation, as other specificities did not profit at 
the same time. We also do not see any rationale for a transiently 
preferential presentation of the m18 epitope during productive 
infection of the lungs. We must rather propose an intrinsic clonal 
property that may even be independent of the epitope. Although 
an explanation is missing, we must note the here observed fact of 
a “coming and going” of epitope-specific antiviral responses in 
the phase of immune reconstitution after HCT.
Interestingly, in studies on primary hCMV infection of 
otherwise healthy immunocompetent individuals, dynamics by 
selection of clonotypes has also been identified as a characteristic 
of the CD8+ T-cell response [reviewed in Ref. (52)].
Deletion of iDes: rationale, Predictions, 
and experimental Verification
Our group has already pursued the strategy to alter immuno-
genicity and antigenicity of mCMV by functional deletion of 
FigUre 2 | high dynamics of epitope-recognition patterns after hcT. Corresponding to Figure 1, frequencies of immunomagnetically purified pulmonary 
CD8+ T cells responding in an ELISpot assay with IFN-γ secretion to stimulation with peptide-loaded stimulator cells were determined for a pool of at least four mice 
per indicated time. Bars represent the most probable numbers, and error bars indicate the 95% confidence intervals determined by linear regression analysis. 
Gray-shaded bars highlight responses to epitopes known to drive memory inflation (MI), namely m123/IE1 and m164. *Epitopes addressed later in this work but not 
yet known at the time when these HCTs were performed. Ø: no peptide added.
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TaBle 2 | Predicted influence of X9ala replacements on steps in peptide processing.a
OrF antigenic peptide score
Proteasome TaP Mhc-i Total Mhc-i ic50 [nM]
const immuno const immuno
M105 TYWPVVSDI 1.01 1.08 0.43 −1.57 −0.13 −0.06 37.29
TYWPVVSDA 1.07 1.05 −0.03 −3.31 −2.26 −2.29 2021.32
m123 YPHFMPTNL 1.02 1.38 0.30 −1.47 −0.15 0.22 29.78
YPHFMPTNA 0.90 1.02 −0.34 −3.25 −2.70 −2.58 1794.48
m145 CYYASRTKL 1.05 1.52 0.57 −1.09 0.53 1.00 12.34
CYYASRTKA 0.93 1.15 −0.08 −2.42 −1.57 −1.35 263.03
m164 AGPPRYSRI 0.95 1.08 0.11 −3.07 −2.01 −1.88 1180.99
AGPPRYSRA 1.01 1.04 −0.35 −4.15 −3.49 −3.46 14199.19
aProcessing predictions (proteasomal cleavage/TAP/MHC class-I combined predictor) were made using the IEDB analysis resource. Steps more critically affected by X9Ala 
replacements are highlighted by red boxes.
FigUre 3 | sketch of antigen processing and presentation. Buffer stop symbols indicate steps at which substitution of the antigenic peptide’s C-terminal 
amino acid with Ala (X9Ala) could block peptide processing. TAP, transporter associated with antigen processing/presentation; ER, endoplasmic reticulum; ERGIC, 
ER-Golgi intermediate compartment. Red oval symbols indicate immune evasion proteins interfering with vesicular flow trafficking of pMHC-I complexes.
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epitopes using site-directed BAC-mutagenesis to introduce a 
point mutation that replaces the MHC-I anchoring C-terminal 
residue of an antigenic peptide with alanine, X9Ala [(25, 43, 
56, 57, 90); for a review of the concept, see Ref. (91)]. Unlike 
deletion of the complete peptide-coding sequence, this strategy 
promises to be “minimally invasive” in that the intended immu-
nological phenotype can be achieved with minimal alteration of 
the corresponding protein and, thus, with the lowest risk of a 
loss of its physiological function. In previous work, cited above, 
we have emphasized the impact of this mutation on anchoring 
the peptide in the hydrophobic pocket of the presenting MHC-I 
molecule to yield a pMHC-I complex (92–94). This is still true 
as an utmost important parameter, as shown by predicted loss of 
binding affinity to MHC-I, indicated by an increase in the IC50 
value (Table 2). However, this mutation can in addition already 
reduce peptide generation by inefficient proteasomal cleavage 
as well as inefficient peptide transport into the ER via the TAP 
prior to peptide loading onto nascent MHC-I molecules (for 
a sketch, see Figure 3; for prediction scores, see Table 2). The 
critical bottlenecks in the pathway may vary between different 
peptides (boxed in Table  2). Combined processing scores for 
all known antigenic peptides in the H-2d haplotype, IDEs and 
non-IDEs (Table  1), which include all steps from proteasomal 
processing to peptide loading (Figure 3), are graphically sum-
marized in Figure 4A. This illustrates the predicted effect of the 
C-terminal mutations I215A, L176A, L459A, and I158A in the 
IDEs M105, m123/IE1, m145, and m164, respectively. In this 
regard, there are no fundamental differences predicted between 
constitutive proteasome and immunoproteasome. As a side 
aspect, the predictions also show that a poor processing score 
does not preclude a peptide to be antigenic. This is probably due 
to favorable parameters operative at steps before entering the 
FigUre 4 | Predicted and experimental efficacies of peptide 
processing. (a) Graphs of combined prediction scores. Processing 
predictions (proteasomal cleavage/TAP transport/MHC class-I combined 
predictor) were made using the IEDB analysis resource. Shown are scores for 
immunodominant (IDE) and non-immunodominant (non-IDE) epitopes. 
Authentic peptides (green bars). C-terminal amino acid substitutions with Ala 
(red bars) reduce the score. (B) Yield of antigenic peptides from MEF infected 
with mutant virus mCMV-Δ4IDE (red bars), lacking IDEs, and the 
corresponding revertant virus mCMV-Δ4IDE-rev expressing IDEs (green 
bars). DL, detection limit.
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proteasome, such as high protein amount, low stability, and effi-
cient ubiquitination for proteasomal import and degradation. In 
theory, the introduced mutation to Ala might lead to misfolding 
of the protein and decreased stability, a factor rather expected to 
enhance proteasomal degradation (95).
Cell surface presentation of pMHC-I complexes for recogni-
tion by the TCR of CD8+ T cells is inhibited by mCMV immune 
evasion proteins m152, retaining complexes in a cis-Golgi/
ER-Golgi intermediate compartment (ERGIC), and m06, rerout-
ing the complexes to late endosomes/lysosomes for degradation 
[reviewed in Ref. (31, 96)]. This interference with the vesicular 
trafficking of pMHC-I complexes, however, is not thought to be 
affected by the C-terminal Ala.
The predictions were experimentally verified by isolating the 
corresponding peptides from lysates of MEF infected with mutant 
virus mCMV-Δ4IDE (57) and the corresponding revertant virus 
mCMV-Δ4IDE-rev (70) (Figure 4B). IDE-representing peptides 
could no longer be isolated when cells were infected with the 
mutant virus, whereas infection with the revertant virus yielded 
high amounts of peptide per cell (up to 104 m123/IE1 and m164 
molecules each). It should be noted that peptide yield reflects the 
number of the corresponding pMHC-I complexes, as peptides 
that fail to bind to MHC-I molecules are degraded. It must be 
considered that peptide yield is proportional to processing effi-
cacy, but is not identical to the amount of processed peptides, 
because immune evasion molecule m152 increases the yield (76) 
by arresting the pMHC-I complexes in the ERGIC, while m06 is 
supposed to reduce the yield by lysosomal degradation (Figure 3). 
To our knowledge, the net outcome of these opposite effects of 
the two immune evasion proteins has never been quantitated. So, 
with this question mark in mind, we operationally take peptide 
yield as an approximation for processing.
Importantly, deletion of the four IDEs had no influence on 
the yield of peptides representing a panel of non-IDEs, namely 
m18, M45, M83, and M84 (Figure 4B). This means that there is 
no notable competition between IDEs and non-IDEs at the levels 
of proteasome and TAP. Furthermore, as each non-IDE has an 
IDE counterpart using the same presenting MHC-I molecule 
(Table 1), there appears to be also no competition at the level of 
MHC-I binding. Finally, with the exception of M84, the amounts 
of non-IDE peptides per cell are not generally much lower than 
that of the IDE peptides, in particular when we consider IDE 
peptide M105.
Functional deletion of the IDEs was confirmed by testing the 
cell surface presentation of IDE–pMHC-I complexes on cells 
infected with IDE-expressing BAC-derived virus mCMV-BACW 
(69) or mutant virus mCMV-Δ4IDE via recognition by the 
cognate CTLL as determined by IFN-γ secretion upon stimula-
tion in an ELISpot assay (Figure  5, upper panels). To account 
for different kinetic classes of viral protein expression, stimulator 
cells in the assay were metabolically arrested in the “IE” phase, 
or in the “E” phase, or were allowed to proceed to the “late” (L) 
phase. As a remark, IE phase expression of the antigenic peptide 
assigned to the E Phase protein m164 has recently been shown to 
result from a transcript starting within an upstream IE gene (89). 
With the exception of a minor residual recognition of the Ala-
variant L459A of the m145 E-phase peptide, which is paralleled 
by a still high constitutive proteasome combined processing score 
(Figure 4A, upper panel), the recognition of IDEs was abolished 
by the C-terminal replacements with Ala.
Finally, with the corresponding non-IDE-specific CTLL, 
we compared presentation of non-IDE pMHC-I complexes in 
FigUre 5 | no impact of iDe deletion on antigenic peptide presentation. MEF were infected with BAC-derived parental virus mCMV-BACW, expressing IDEs 
(green bars), or mutant virus mCMV-Δ4IDE (red bars), lacking IDEs. Infected MEF presenting antigenic peptides derived from the three kinetic phases of viral gene 
expression, “immediate early” (IE), “early” (E), and “late” (L), were used as stimulator cells in an ELISpot assay. Cells of epitope-specific CTLL were used as 
responder cells. Bars represent frequencies of CTL responding to the stimulation with secretion of IFN-γ.
FigUre 6 | sketch of the experimental regimens. (a) Infection of 
BALB/c mice (destined as recipients for HCT), immunocompromised by 
hematoablative total-body γ-irradiation (flash symbol) but with no HCT being 
performed. Filled and empty capsid virus pictograms indicate presence and 
absence of IDEs, respectively. (B) HCT performed by intravenous transfer of 
bone marrow cells (BMC).
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presence or absence of IDEs after infection with viruses mCMV-
BACW and mCMV-Δ4IDE, respectively (Figure 5, lower panel). 
At a glance, presence or absence of IDEs had no notable effect on 
the presentation of four tested non-IDEs. Specifically, presenta-
tion of non-IDEs did not profit from the absence of IDEs. This 
leaves us with the conclusion that the phenomenon of “immuno-
dominance” is not regulated at the levels of antigen processing or 
presentation.
absence of iDes Does not negatively 
influence control of infection after hcT
We initiated this study with the question if absence of an IDE-
specific CD8+ T-cell reconstitution would prevent control of 
infection after HCT as seen previously after pan-CD8+ T-cell 
depletion [(44, 45), see also the accompanying Review article in 
this issue of Frontiers in Immunology]. To approach this question, 
we compared the infection of immunocompromised recipients 
with viruses expressing or not expressing IDEs first in the 
absence of hematopoietic reconstitution and then in the presence 
of hematopoietic reconstitution after HCT (for a sketch of the 
experimental models, see Figures 6A,B, respectively).
Testing infection after hematoablative treatment, with no 
HCT being performed, is important for evaluating viral repli-
cative fitness in vivo in order to detect potential attenuation of 
mutant virus for reasons unrelated to reconstitution of immune 
control. Although the above described C-terminal replace-
ments with Ala in the IDE peptide sequences are the minimal 
procedure required to achieve the intended immunological 
loss-of-presentation phenotype, one can never exclude an effect 
on protein folding and function. As explained in detail in recent 
reports (97, 98), virus spreads and replicates exponentially 
over time in organs of an immunodepleted host, which leads 
to log-linear growth regression lines with the vDT as the 
growth constant that reveals replicative fitness. Unlike growth 
curves in cell culture, this in vivo approach has the advantage 
to incorporate all cell types that constitute the tissues of tested 
organs in the natural microanatomical context. This experi-
mental protocol (Figure 6A) revealed a minor increase in vDT 
(slower replication), and, thus, a slight attenuation, of mutant 
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virus mCMV-Δ4IDE in the spleen compared to mCMV-BACW 
(Figure 7, upper panels). This attenuation was clearly related to 
the mutations since the growth-deficiency phenotype of mCMV-
Δ4IDE was reversed to normal growth in the IDE-expressing 
revertant virus mCMV-Δ4IDE-rev. Although we could map this 
attenuation to the M105-Ala variant I215A (data not shown), 
impaired helicase-primase function of protein M105 (99) is 
unlikely the reason for growth attenuation in the spleen, as no 
attenuation of mCMV-Δ4IDE was seen in lungs and liver of the 
same mice (Figure 7, center and lower panels, respectively). We 
did not further investigate the reason for the spleen-selectivity 
of this attenuation, but it likely relates to infected cell type(s) 
present in the spleen but not in lungs and liver, or to a higher 
residual innate immunity in the spleen. It should be noted that 
in absence of HCT, immunodepleted mice die of multiple-organ 
CMV disease from day 10 onward (35).
With these results in mind, we extended the model by perform-
ing HCT, that is by transfer of syngeneic BMCs to the recipients 
after hematoablative conditioning and followed by intraplantar 
infection (Figure 6B). The reconstitution led to survival of the 
recipients with control of both viruses, mCMV-Δ4IDE and 
mCMV-Δ4IDE-rev, in spleen, lungs, and liver (Figure  8). In 
the spleen, the IDE-deletion mutant replicated to lower levels 
already in the first 2 weeks after HCT (Figure 8, upper panel, 
P  =  0.0022), before reconstitution of CD8+ T cells becomes 
detectable (data not shown). Thus, in accordance with the slower 
replication in the spleen of immunodepleted, unreconstituted 
mice (recall Figure  7, upper panel), subsequent immunologi-
cal control of mCMV-Δ4IDE in the spleen is obscured by the 
site-specific attenuation of this mutant. In the lungs, however, 
this caveat does not apply, as mutant and revertant virus rep-
licated there with no difference until week 3 (Figure 8, center 
panel; P =  0.4558), the time when reconstituted CD8+ T cells 
first appear in the lungs (recall Figures 1 and 2). Surprisingly, 
at the peak of CD8+ T-cell infiltration at 4 weeks and at all later 
times, the mutant virus was controlled more efficiently than the 
revertant virus and became latent between 16 and 20 weeks when 
the revertant virus was still in low-level persistent replication. 
Finally, in the liver, both viruses replicated equally at all times, 
with latency being established for both viruses from week 4 
onward.
We determined the status of epitope-specific CD8+ T-cell 
reconstitution in the latently infected spleens by stimulation with 
a genome-wide open reading frame (ORF) library of transfected 
cells (Figure  9, left panels) and by stimulation with saturating 
doses of synthetic peptides representing the known epitopes 
(Figure 9, right panels), in both cases measuring the frequency 
of stimulated CD8+ T cells by intracellular IFN-γ. In the case of 
infection with mCMV-Δ4IDE-rev the two epitopes long known as 
epitopes that induce MI, namely m123/IE1 and m164 (see above), 
dominated the memory pool, but memory cells specific for the 
more recently defined IDEs M105 and m145 were also detect-
able in both assays. In addition, minor responses were detected 
by the ORF library approach to ORFs m05, M54, and M86. 
After infection with mutant virus mCMV-Δ4IDE, IDE-specific 
memory cells were missing as expected. Interestingly, although 
the ORF library revealed minor reactivity to ORFs m04, m20, 
M54, and m153, none of the known non-IDE epitopes appeared 
to notably profit from the absence of IDEs. Note that, at the time 
of the experiment, the M54 peptide was not yet known and has 
in the meantime been described as an epitope that indeed profits 
from the absence of IDEs (70), in accordance with its enhanced 
appearance in the ORF library assay.
In conclusion, the results were clear in that IDEs were not 
essential for control of infection after HCT and were not even of 
advantage, as at least pulmonary infection was controlled even 
somewhat better in the absence of IDEs.
cD8+ T cells specific for non-iDes Form 
Protective nodular inflammatory Foci
The data thus far gave the unequivocal message that absence 
of IDE-specific CD8+ T cells during reconstitution after HCT 
differs fundamentally from a pan-CD8+ T-cell depletion in that 
the recipients still control the infection and survive, whereas 
the pan-depletion led to lethal multiple-organ CMV disease 
in 100% of the HCT recipients (see the accompanying Review 
article in this issue of Frontiers in Immunology). Our proposed 
explanation is that CD8+ T cells specific for many non-IDEs, 
most of which may have an individual frequency below 
assay detection limit, collectively mount an efficient antiviral 
response. As we have shown previously, antiviral protection has 
a microanatomical correlate in the formation of NIF in which 
CD8+ T cells gather around infected tissue cells for confining 
the infection by preventing intra-tissue spread (45, 100, 101). 
Importantly, the formation of NIF is epitope specific in that 
infected cells must present the cognate epitope (43, 90). We, 
therefore, addressed the question if non-IDE-specific CD8+ T 
cells can form NIF in mice infected with mCMV-Δ4IDE, which 
would indicate that the non-IDEs are indeed presented in situ 
by infected tissue cells and recognized in an epitope-specific 
manner by cognate CD8+ T cells present in a cell population 
devoid of IDE-specific cells.
We approached this question in the previously described 
criss-cross adoptive CD8+ T-cell transfer/immunotherapy model 
(56, 57) by using mutant or revertant virus for donor mouse 
priming as well as for the infection of recipients immunocom-
promised by hematoablative treatment (Figure 10A). In essence, 
infection of the liver was controlled in all four donor–recipient 
combinations. Notably, the control was somewhat more efficient 
in mCMV-Δ4IDE-infected recipients, regardless of the donor 
IDE equipment, and least efficient when IDE-specific cells were 
missing in the donor cell population transferred into recipients 
presenting IDEs. Most importantly, liver infection was efficiently 
controlled also by the CD8+ T-cell population that is devoid of 
IDE-specificity and even upon transfer into recipients not pre-
senting IDEs on the infected cells (Figure  10B). In absence of 
CD8+ T-cell transfer, infection was not controlled and NIF were 
not formed (Figure 10C, image C1), which excludes protective 
NIF formation by residual other potentially CMV-protective cell 
types of innate or adaptive immunity, including cells also express-
ing CD3ϵ detected in the two-color IHC, such as CD4+ T cells, γ/δ 
T cells, and NKT cells. Importantly, protective NIF were formed 
by the tissue-infiltrating CD8+ T cells in all four cell transfer 
FigUre 7 | Viral replicative fitness in organs of immunocompromised mice. Following regimen “A” of Figure 6, log-linear growth curves in the spleen (top), 
lungs (center), and liver (bottom) were determined over a period of 10 days for the three viruses indicated. For graphical clarity, symbols depict only the median 
values of data from three mice per time point measured, though regression lines were calculated by including data from all individual mice and all assay times. Dotted 
lines demarcate the 95% confidence areas of the corresponding regression lines. Virus attenuation is indicated by an increased value of the viral doubling time, vDT, 
and thus by a reduced slope of the regression line. The 95% confidence intervals for vDT are given in parentheses. p.i., post-infection. Virus titers in spleen and lungs 
refer to the whole organ, the numbers of IHC-detected, infected (IE1+) liver cells (mostly hepatocytes) refer to representative 10 mm2 areas of liver tissue sections.
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FigUre 8 | influence of iDes on the course of infection in hcT recipients. Following regimen “B” of Figure 6, virus replication in HCT recipients infected with 
mCMV-Δ4IDE, lacking IDEs (open circles), or mCMV-Δ4IDE-rev, expressing IDEs (filled circles), was quantitated over a period of 20 weeks in the spleen (top), lungs 
(center), and liver (bottom) during hematopoietic reconstitution. Symbols represent data from individual mice, dashes represent the median values. Virus titers in 
spleen and lungs refer to the whole organ, the numbers of IHC-detected, infected (IE1+) liver cells (mostly hepatocytes) refer to representative 10-mm2 areas of liver 
tissue sections. P-values compare data for mutant virus (open circles) and revertant virus (filled circles) cumulated for the time points that precede the reconstitution 
of CD8+ T cells.
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groups, as shown representatively for the IDE:IDE combination 
as the positive reference scenario (Figure 10C, image C2) and for 
the non-IDE:non-IDE combination as the group under investiga-
tion (Figure 10C, image C3).
In conclusion, non-IDE-specific CD8+ T cells can recognize 
their cognate non-IDE epitopes presented on infected host tis-
sue cells for the formation of NIF that confine and eventually 
terminate tissue infection.
DiscUssiOn
The mouse model of CMV infection [reviewed in Ref. (34)] has 
proven its validity for approaching medical questions that cannot 
be addressed in patients and that are logistically too demanding 
to be readily approached in non-human primate models [for 
reviews, see Ref. (6, 102)]. Considering advantages and limita-
tions of any model, the mouse model, to the very least, can make 
FigUre 9 | Deletion of iDes is not associated with global alteration in epitope-recognition patterns. At 6 months after HCT and infection with mCMV-
Δ4IDE-rev, expressing IDEs (upper panels), or mCMV-Δ4IDE, lacking IDEs (lower panels), epitope-specific reconstitution of CD8+ T cells in the spleen was monitored 
and quantitated by cytofluorometric intracellular IFN-γ assays of cells responding to sensitization. (Left panels), mCMV genome-wide ORF library screening. (Right 
panels), screening with synthetic peptides corresponding to known epitopes. Arrows point to ORF library positions of epitopes deleted in mutant virus mCMV-
Δ4IDE.
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predictions for specific evaluation in lower sample numbers of 
non-human primates or in observational clinical studies (for a 
more detailed discussion, see the accompanying Review article 
in this issue of Frontiers in Immunology).
It is a long-established clinical observation that reconstitution 
of an antiviral CD8+ T-cell response correlates with control of 
reactivated hCMV infection after HCT (29, 30). It is also known 
that a limited but individually distinct set of viral epitopes, the 
IDEs, dominates the antiviral response in quantitative terms in 
any individual person based on her/his individual immunogenetic 
makeup and virus strains harbored in latency (46). This has led 
to the logical opinion that monitoring of immunoreconstitution 
after HCT, vaccine development, and cytoimmunotherapy should 
aim for IDE-specific CD8+ T cells. Focus on IDEs is further sup-
ported by the relative ease to detect and quantitate these responses 
and to sort a sufficient number of epitope-specific CD8+ T cells for 
adoptive immunotherapy, an approach principally successful in 
human trials (40, 41) and in the mouse model (36). Although IDE-
specific CD8+ T cells can undoubtedly be protective and are, thus, 
not a “wrong” choice, the question remained if antiviral protection 
depends on IDEs, and if IDEs are necessarily the “best” choice.
Our own previous work on cytoimmunotherapy in the mouse 
model, specifically adoptive transfer of non-IDE-specific CTLL 
or polyclonal memory CD8+ T cells devoid of IDE-specificities 
[(57), and reviewed in Ref. (32–34)], corroborated by studies of 
D.H. Spector´s group on genetic vaccination in the immunocom-
petent mouse challenge model (55), indicated an at least equal or 
even better antiviral protection exerted by CD8+ T cells recogniz-
ing non-IDEs. This finding is in accordance with other systems 
reviewed recently (103). In CMV infections, prediction of the 
protection-inducing capacity of an epitope is further complicated 
by an additional parameter, namely by the action of immune 
evasion molecules that interfere with cell surface presentation of 
pMHC-I complexes. This has led to the notion that antigens and 
“immunoevasins” are opponents in CMV immune surveillance 
(31). As a most prominent example for a “non-protective” IDE, 
a CTLL specific for the mCMV ORF M45-derived Db-presented 
peptide HGIRNASFI (104) fails to protect immunocompromised 
C57BL/6 mice, unless immune evasion molecule m152 is deleted 
to allow cell surface presentation of pM45-Db complexes (105). 
Interestingly, the inhibitory effect of immune evasion molecules is 
linked to peptide processing efficacy in infected cells in that inhibi-
tion is complete for the poorly processed M45 peptide (76), but 
becomes leaky when peptide processing is enhanced by IFN-γ to 
yield higher numbers of pM45-Db complexes saturating the inhibi-
tory capacity of immune evasion molecules (106). More recently, 
the Kd-presented ORF M105 epitope (Table 1) has been identified 
as a second example of a non-protective IDE that turns into being 
protective when immune evasion molecules are deleted (33).
Here, we have expanded our previous work in the murine 
model by addressing the question if IDE-specificity of CD8+ T 
cells is essential for controlling CMV infection in the specific 
context of immunoreconstitution after HCT when T-cell 
lymphopoiesis, thymic selection, and priming take place under 
conditions imposed by the infection, including an altered 
cytokine-chemokine milieu. This is a situation that has a clini-
cal correlate and that differs essentially from adoptive transfer 
models that are based on already differentiated memory or effec-
tor cells. Studying the role for IDEs under conditions of HCT is 
particularly important in the light of previous findings that CD8+ 
T cells are dispensable for CMV control in selectively depleted but 
otherwise immunocompetent mice (107, 108), whereas deple-
tion of CD8+ T cells during immunoreconstitution in infected 
HCT recipients is inevitably lethal (44, 45). We, thus, began our 
FigUre 10 | non-iDe-specific recognition of infected host tissue cells identified by the formation of protective nodular inflammatory foci (niF). (a) 
Sketch of the experimental strategy of criss-cross adoptive transfer of spleen-derived memory CD8+ T cells primed in presence or absence of IDEs into recipient 
mice presenting or not presenting IDEs on their tissue cells after infection with the viruses mCMV-Δ4IDE-rev and mCMV-Δ4IDE, respectively. (B) Control of liver 
infection in the four possible transfer combinations. The numbers of IHC-detected, infected (IE1+) liver cells (mostly hepatocytes) were determined on day 11 and 
refer to representative 10-mm2 areas of liver tissue sections. Filled circles represent individual mice, with the respective median values marked by a dash. Ø, no cells 
transferred. Statistical significance of differences is indicated comparing groups of interest. (c) Two-color IHC with red staining of intranuclear viral IE1 protein, 
identifying infected cells, and black staining of CD3ϵ, identifying tissue-infiltrating T cells. (C1) Foci of infection with mCMV-Δ4IDE-rev formed by many infected (red) 
cells in the group with no CD8+ T-cell transfer. Images for infection with mCMV-Δ4IDE are alike. (C2) NIF formed by infiltrating CD8+ T cells (black) in the transfer 
combination IDE:IDE, indicating confinement of the infection to single infected cells (red). (C3) NIF formed by infiltrating non-IDE-specific CD8+ T cells (black) in the 
transfer combination non-IDE:non-IDE, likewise confining the infection to single infected cells (red). The bar marker applies to all images and represents 50 μm.
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study with the working hypothesis that a failure to reconstitute 
a quantitatively dominant IDE-specific CD8+ T-cell response 
might be as lethal as pan-CD8+ T-cell depletion or might end up 
in persistent productive infection or at least in a delayed clearance 
of productive infection. The data are unequivocal in demonstrat-
ing that IDE-specific immunoreconstitution is neither essential 
nor of additional benefit.
Epitope-specific immunomonitoring of antiviral CD8+ T cells 
reconstituted following syngeneic HCT revealed that the epitope-
recognition patterns vary between HCTs performed under 
nominally identical conditions, and are highly dynamic over 
time within each HCT, with the only constant feature that at late 
times the initially broader response focuses on the MI-inducing 
epitopes. Strong clonal expansions and high dynamics have been 
described also for the T-cell response to hCMV [reviewed in Ref. 
(52)]. Interestingly, in HCT #3 (Figure 2), CD8+ T cells specific 
for the non-IDE epitope m18 expanded to high numbers between 
weeks 3 and 4, so that one could have classified it as an IDE. 
However, this expansion was transient and the m18 response 
was completely lost thereafter. It appears as if certain CD8+ T-cell 
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clones stochastically can gain a temporary growth advantage, 
independent of their classification as being IDE- or non-IDE 
specific, a classification that is usually based on the specificity 
hierarchy in immunocompetent mice. It is worthwhile consider-
ing that an unintended encounter with unrelated antigens during 
the long observation period can shape the memory pool specific 
for the pathogen under investigation, a parameter of epitope 
hierarchy dynamics and response plasticity experimentally 
documented by the group of Welsh (109, 110). Such an influence 
varies unpredictably between different HCTs, and obviously, 
encounters with unrelated antigens are unavoidably the rule in 
the medical reality of patients. The finding that the response to 
MI-inducing epitopes prevails on the long run is explained by 
repetitive intrinsic episodes of antigenic peptide presentation and 
memory T-cell restimulation based on sporadic viral gene expres-
sion events during latency, which can be driven by inflammatory 
cytokine signaling during pathogen encounters [(111); reviewed 
in Ref. (27, 28)].
Genetic deletion of the four prominent IDEs of mCMV 
presented in the H-2d haplotype was here found to have no sig-
nificant impact on the processing and presentation of non-IDEs 
in infected cells, which excludes competition between IDEs and 
non-IDEs at any step of this pathway (Figure 3) as a reason for 
immunodominance, a conclusion that is in accordance with cur-
rent opinion [reviewed in Ref. (103)]. Notably, although immu-
nodominance could be defined at the level of TCR-pMHC-I 
interaction driving T-cell expansion, we did not observe notable 
and reproducible expansion of CD8+ T cells specific for defined 
non-IDEs in the absence of IDEs upon infection of mice with 
mutant virus mCMV-Δ4IDE during either acute or latent infec-
tion in the spleen [(57) and this report, respectively]. Moreover, 
genome-wide ORF library screenings did not indicate a broad 
emergence of new specificities in the spleen during either acute 
or latent infection [(57) and this report, respectively], with the 
notable exception of M54 in the lungs during acute infection after 
HCT (70). Nonetheless, absence of IDEs did not impair the con-
trol of infection after HCT (Figure 8). A hint to an explanation is 
given by previous work on the deletion of the two MI-inducing 
IDEs, m123/IE1 and m164 (56), showing that epitope hierarchies 
change when related to functional avidity, and that high quantity 
defining “immunodominance” is based primarily on low-avidity 
cells detected with high concentrations of exogenously loaded 
synthetic peptides. As presentation of naturally processed 
antigenic peptides in host tissue cells is a limiting factor, and 
as high-avidity is a predictor for protective activity in vivo (33, 
112), low-avidity responses to IDEs likely contribute little to 
protection. Work in progress indicates a gain of avidity in the pool 
of non-IDE-specific CD8+ T cells primed in the absence of IDEs 
(Rafaela Holtappels, preliminary data not shown), which would 
offer an explanation for the more efficient control of mutant virus 
mCMV-Δ4IDE in the lungs (Figure 8).
The critical question remained, however, if non-IDE-specific 
CD8+ T cells protect by recognition of non-IDEs presented 
on infected host tissue cells or if deletion of IDEs might have 
called up alternative mechanisms of immune control. Antiviral 
protection in  vivo has a microanatomical correlate in the for-
mation of NIF, clusters of focally infiltrating CD8+ T cells that 
attack infected tissue cells and thereby confine and eventually 
clear productive infection (referenced above). Importantly, NIF 
formation requires presentation of the cognate epitope (90). 
Here, our presented finding that protective NIF are formed by 
non-IDE-specific CD8+ T cells in liver tissue infected by mCMV-
Δ4IDE verifies protection by recognition of presented non-IDEs.
In conclusion, our study revealed that IDEs are not essential for 
control of CMV infection in the context of HCT. Importantly, this 
implies that antigenicity/immunogenicity-loss mutations in IDEs 
will not likely lead to immune escape of the virus. For adoptive 
immunotherapy, this predicts a robustness of the therapy toward 
antigenically relevant proteomic differences in the hCMV strains 
harbored in latently infected HCT patients.
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